Isy Petit

Isy Petit

Auto-generated profile, based on publicly available information

Isy Petit

U1248 Pharmacology & Transplantation, Inserm, Université de Limoges, Limoges, France

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2026 in Drug Metabolism and Disposition
Verified
Journal Article
Open access
IPIsy Petit
Isy Petit
JBJean-Sébastien Bernard
Jean-Sébastien Bernard
QFQuentin Faucher
Quentin Faucher
DCDorian Chastagner
Dorian Chastagner
HAHélène Arnion
Hélène Arnion
NVNicolas VEDRENNE
Nicolas VEDRENNE
Membrane transporters play a central role in the absorption, distribution, metabolism, and elimination of drugs. Beyond drug handling, these transporters regulate the transport of endogenous metabolites, contributing to physiological homeostasis. Their activity is regulated not only by intrinsic cellular mechanisms but also by signals from distant organs. Understanding these processes is crucial for accurately predicting both local and systemic pharmacokinetics, as transporter function influences drug concentrations and effects at target tissues and throughout the organism. However, most current in vitro models do not recapitulate interorgan interactions or the dynamic regulation of transporter function. Microphysiological systems, particularly organ-on-chip, offer a promising approach to studying transporter biology in a more integrated and physiologically relevant context. This review provides an overview of the development and application of organ-on-chip technologies to investigate drug transporters and their regulation. Although significant technical progress has been made, these systems often remain focused on engineering or industrial goals, with limited impact on fundamental biological questions. Moreover, the high degree of customization and widespread use of homemade organ-on-chip models, with diverse materials, geometries, and cell sources, have created substantial barriers to reproducibility and cross-laboratory comparison. We here assess the current state of the field and identify gaps in modeling transporter regulation and interorgan communication. We also explore the potential of organ-on-chip to advance our understanding of systemic pharmacology. This review aims to reposition organ-on-chip platforms not only as technological demonstrators but also as experimental systems capable of generating new biological insights into transporter function and organ crosstalk. SIGNIFICANCE STATEMENT: Membrane transporters are central regulators of drug disposition and systemic homeostasis, yet their interorgan regulation remains poorly captured by conventional models. This review highlights how organ-on-chip technologies can bridge this gap, enabling mechanistic investigation of transporter function and advancing predictive, human-relevant pharmacology.

15 October 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
IPIsy Petit
Isy Petit
QFQuentin Faucher
Quentin Faucher
JBJean-Sébastien Bernard
Jean-Sébastien Bernard
PGPerrine Giunchi
Perrine Giunchi
AHAntoine Humeau
Antoine Humeau
FMFlorent Di Meo
Florent Di Meo
Deciphering the sources of variability in drug responses requires to understand the processes modulating drug pharmacokinetics. However, pharmacological research suffers from poor reproducibility across clinical, animal, and experimental models. Predictivity can be improved by using Organs-on-Chips, which are more physiological, human-oriented, micro-engineered devices that include microfluidics. OoC are particularly relevant at the fundamental and preclinical stages of drug development by providing more accurate assessment of key pharmacokinetic events. We have developed a proximal tubule-on-a-chip model combining commercial microfluidic and chip technologies. Using the RPTEC/TERT1 cell line, we set up a dual-flow system with antiparallel flows to mimic the dynamics of blood and urine. We assessed transporters mRNA expression using RT-qPCR, cellular polarization and protein expression via immunofluorescence and confocal microscopy, and monitored the transcellular transport of a list of prototypic xenobiotics by determining their efflux ratios with LC-MS/MS. Our results show that flow exposure significantly modulate mRNA expression of drug membrane transporters compared to static conditions. Dynamic conditions also enhance cell polarization, as evidenced by preferential basal and apical expressions of Na+/K+-ATPase, P-gp, OCT2, and MATE1, as well as the cellular secretory profile. We demonstrated unidirectional transcellular transport of a cationic substrate (metformin) with a higher efflux than influx ratio, inhibited with a specific OCT2 inhibitor, thus confirming the relevance of our proximal tubule- on-a-chip set up for cation transport investigations. Our proximal tubule-on-a-chip can also be used to explore the interactions between transporters, xenobiotics, and endogenous metabolites, possibly involved in the variability of individual drug responses. This study provides additional evidence that OoC can bridge the gaps between systemic and local pharmacokinetics, i.e., drug concentration close to its target, at the fundamental and preclinical stages. Highlights: Cell exposure to flow shear stress modulate mRNA drug membrane transporters and cell polarization of proximal tubule Proximal tubule-on-chip relying on RPTEC/TERT1 cell line is a suitable platform for assessing transcellular cationic transport OCT2 and MATE are involved in potential drug-endogenous metabolite interactions Cell exposure to xenobiotics and endogenous metabolites modulate the drug transporters expression. Graphical Data Statement: Original microscopy pictures, raw data for metabolomics and other data are available upon reasonable request.